-
Mashup Score: 0Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma - 7 month(s) ago
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Grants Priority Review to BLA for Odronextamab in FL and DLBCL - 7 month(s) ago
Priority review to the biologics license application for odronextamab has been granted by the FDA for adult patients with follicular lymphoma and diffuse large B-cell lymphoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
TARRYTOWN, N.Y. , Aug. 17, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R)
Source: investor.regeneron.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @EMA_News to review a marketing authorization application for CD20 × CD3, a bispecific antibody, for adults with R/R #FL or #DLBCL who progress after ≥2 prior systemic therapies, following supporting data from ELM-1 and ELM-2. https://t.co/NN7cnVSt2L. #lymsm #mednews https://t.co/pIuQuHfFDc
-
-
Mashup Score: 0
Sarah C. Rutherford, MD, discussed how findings from her research could impact the current guidelines for follicular lymphoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Prognostic Value of PET Status for Patients With R/R Follicular Lymphoma Undergoing AutoSCT - 9 month(s) ago
Pre-autologous stem cell transplantation positron emission tomography status has strong prognostic value and may help to improve the risk stratification and selection of patients for autoSCT, according to a retrospective analysis.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Toby A. Eyre, MD, and coauthors, the results of this analysis on patients with R/R #FollicularLymphoma "suggest that pre-SCT PET status is of clear prognostic value and may help to improve the selection of patients for autoSCT." Read more: https://t.co/vC2GS71nmy #FL https://t.co/PDQFyUPCE2
-
-
Mashup Score: 0
With these results, Breyanzi has now demonstrated clinically meaningful benefit across the broadest array of B-cell malignancies of any CD19-directed CAR T cell therapy, underscoring the company’s leadership in advancing innovative therapies for many types of hematological malignancies Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from two studies, TRANSCEND FL, an…
Source: news.bms.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The phase 3 GALLIUM trial results indicate histological transformation in advance-stage follicular lymphoma was associated with poor overall survival rates.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PI3Kδ Inhibitor Linperlisib Clinical Activity Among Patients With R/R Follicular Lymphoma - 1 year(s) ago
Oral PI3Kδ inhibitor linperlisib displayed compelling clinical activity and manageable tolerability among patients with R/R follicular lymphoma who had received 2 or more prior systemic therapies, according to a phase 2 trial.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In the diffuse large B-cell lymphoma and follicular lymphoma cohorts of the ELM-1 and ELM-2 trials, odronextamab led to high overall response rates.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Here, Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of #mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma #FL. Learn more: https://t.co/ZHd9YWHpC0 @DrMatasar @RutgersCancer #MedTwitter https://t.co/ikMe8VyB6C